Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/369086 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850234654858149888 |
|---|---|
| author | Peter Rohon Jana Vondrakova Anna Jonasova Milena Holzerova Marie Jarosova Karel Indrak |
| author_facet | Peter Rohon Jana Vondrakova Anna Jonasova Milena Holzerova Marie Jarosova Karel Indrak |
| author_sort | Peter Rohon |
| collection | DOAJ |
| description | Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies are mandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoeconomy. |
| format | Article |
| id | doaj-art-162425a9b2bc4a60bddc8f6047ef6ab8 |
| institution | OA Journals |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-162425a9b2bc4a60bddc8f6047ef6ab82025-08-20T02:02:33ZengWileyCase Reports in Hematology2090-65602090-65792012-01-01201210.1155/2012/369086369086Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case ReportsPeter Rohon0Jana Vondrakova1Anna Jonasova2Milena Holzerova3Marie Jarosova4Karel Indrak5Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky’ University, Olomouc, IP Pavlova 6, 775 20 Olomouc, Czech RepublicDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky’ University, Olomouc, IP Pavlova 6, 775 20 Olomouc, Czech RepublicFirst Department of Medicine, Charles University General Hospital, U nemocnice 2, 128 08 Prague, Czech RepublicDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky’ University, Olomouc, IP Pavlova 6, 775 20 Olomouc, Czech RepublicDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky’ University, Olomouc, IP Pavlova 6, 775 20 Olomouc, Czech RepublicDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky’ University, Olomouc, IP Pavlova 6, 775 20 Olomouc, Czech RepublicEpigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies are mandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoeconomy.http://dx.doi.org/10.1155/2012/369086 |
| spellingShingle | Peter Rohon Jana Vondrakova Anna Jonasova Milena Holzerova Marie Jarosova Karel Indrak Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports Case Reports in Hematology |
| title | Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports |
| title_full | Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports |
| title_fullStr | Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports |
| title_full_unstemmed | Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports |
| title_short | Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports |
| title_sort | treatment of chronic myelomonocytic leukemia with 5 azacytidine case reports |
| url | http://dx.doi.org/10.1155/2012/369086 |
| work_keys_str_mv | AT peterrohon treatmentofchronicmyelomonocyticleukemiawith5azacytidinecasereports AT janavondrakova treatmentofchronicmyelomonocyticleukemiawith5azacytidinecasereports AT annajonasova treatmentofchronicmyelomonocyticleukemiawith5azacytidinecasereports AT milenaholzerova treatmentofchronicmyelomonocyticleukemiawith5azacytidinecasereports AT mariejarosova treatmentofchronicmyelomonocyticleukemiawith5azacytidinecasereports AT karelindrak treatmentofchronicmyelomonocyticleukemiawith5azacytidinecasereports |